Professor Mikkel Østergaard
Quick facts
Marketed products
- Apremilast Oral Tablet
- Secukinumab 150 milligram [Cosentyx] · Immunology
Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: